📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Enantioselective Synthesis of Atropisomeric Drug Candidates by Biocatalytic Deracemization

Lead Research Organisation: University of Bristol
Department Name: Chemistry

Abstract

Atropisomers are molecules which possess axial chirality, a property which is becoming increasingly common in drug motifs. Methods for their enantioselective synthesis include kinetic, dynamic kinetic, and dynamic thermodynamic resolution, however there are issues with these approaches; namely kinetic resolution has a limit of 50% yield, dynamic kinetic resolution is limited in functional group compatibility, and dynamic thermodynamic resolution can require chiral auxiliaries, making it less atom economical.

In the Collins and Clayden groups it has been proposed that the enantioselective synthesis of atropisomers could be achieved via deracemization. In the proposed approach, we will use biocatalysis as a tool to generate the required cyclic reaction network which will underpin deracemization. Biocatalytic deracemization of point-chiral molecules has previously been achieved with enzymes, with yields of >99% and ees of >99% reported, but deracemization has not yet been applied to the enantioselective synthesis of atropisomers.

The goal of this project will be to identify conditions for the deracemization of biaryl atropisomers and explore the scope of the methodology through the systematic variation of steric and electronic features on the configurationally stable biaryl core. In addition, we hope to develop a high-throughput screening method for the identification of hits and for reaction optimization.

Planned Impact

1. PEOPLE: We will train students with skills that are in demand across a spectrum of industries from pharma/biotech to materials, as well as in academia, law and publishing. The enhanced experience they receive - through interactive brainstorming, problem and dragons' den type business sessions - will equip them with confidence in their own abilities and fast-track their leadership skills. 100% Employment of students from the previous CDT in Chemical Synthesis is indicative of the high demand for the skills we provide, but as start-ups and SMEs become increasingly important in the healthcare, medicine and energy sectors, training in IP, entrepreneurship and commercialisation will stimulate our students to explore their own ventures. Automation and machine learning are set to transform the workplace in the next 20 years, and our students will be in the vanguard of those primed to make best use of these shifts in work patterns. Our graduates will have an open and entrepreneurial mindset, willing to seek solution to problems that cross disciplines and require non-traditional approaches to scientific challenges.

2. ECONOMY: Built on the country's long history of scientific ingenuity and creativity, the >£50bn turnover and annual trade surplus of £5 bn makes the British chemical sector one of the most important creators of wealth for the national economy. Our proposal to integrate training in chemical synthesis with emerging fields such as automation/AI/ML will ensure that the UK maintains this position of economic strength in the face of rapidly developing competition. With the field of drug development desperately looking for innovative new directions, we will disseminate, through our proposed extensive industrial stakeholders, smarter and more efficient ways of designing and implementing molecular synthesis using automation, machine learning and virtual reality interfaces. This will give the UK the chance to take a world-leading position in establishing how molecules may be made more rapidly and economically, how compound libraries may be made broader in scope and accessed more efficiently, and how processes may be optimized more quickly and to a higher standard of resilience. Chemical science underpins an estimated 21% of the economy (>£25bn sales; 6 million people), so these innovations have the potential for far-reaching transformative impact.

3. SCIENCE: The science emerging from our CDT will continue to be at the highest academic level by international standards, as judged by an outstanding publication record. Incorporating automation, machine learning, and virtual reality into the standard toolkit of chemical synthesis would initiate a fundamental change in the way molecules are made. Automated methods for making limited classes of molecules (eg peptides) have transformed related biological fields, and extending those techniques to allow a wide range of small molecules to be synthesized will stimulate not only chemistry but also related pivotal fields in the bio- and materials sciences. Synthesis of the molecular starting points is often the rate-limiting step in innovation. Removing this hurdle will allow selection of molecules according to optimal function, not ease of synthesis, and will accelerate scientific progress in many sectors.

4. SOCIETY: Health benefits will emerge from the ability of both academia and the pharmaceutical industry to generate drug targets more rapidly and innovatively. Optimisation of processes opens the way for advances in energy efficiency and resource utilization by avoiding non-renewable, environmentally damaging, or economically volatile feedstocks. The societal impact of automation will extend more widely to the freeing of time to allow more creative working and also recreational pastimes. We thus aim to be among the pioneers in a new automation-led working model, and our students will be trained to think through the broader consequences of automation for society as a whole

Publications

10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
EP/S024107/1 30/09/2019 30/03/2028
2741967 Studentship EP/S024107/1 30/09/2022 29/09/2026 Nicholas O'Donoghue